A little earlier than expected, Spark’s announces Luxturna pricing, $850k
RxC International has evaluated the Luxturna clinical story and its market opportunity, including critical questions regarding this highly-watched commercial launch. Here's what you need to know.
Monthly Gene Therapy Business Review - December 2017
This month, the most noteworthy gene therapy stories include:
- First Mover Advantage? Gilead Blazes Trail for Competition
Newly-Published Yescarta Study Raises Safety Concerns
Results from Hemophilia Gene Therapy Studies Prompt Pricing Questions...Again
Read about these developments and our commercial insights into the ongoing evolution of the gene therapy market.
Monthly Gene Therapy Business Review - November 2017
November saw some important moments in gene therapy. We have summarized the most noteworthy and included the remaining in our news and updates sections.
Landmark Month Sees Second Gene Therapy Approved and Other Advances
October was a landmark month for gene therapies with the approval of the second-ever gene therapy in the US, Yescarta (axicabtagene ciloleucel) from Kite and Gilead. The prior approval of Novartis’ Kymriah is more proof that gene therapies are set to shake up the pharma industry. Gene therapies saw other wins as Luxturna, Spark’s treatment for Leber congenital amaurosis, received the FDA’s recommendation for approval and Bluebird Bio’s interim data report for its gene therapy Lenti-D to treat cerebral adrenoleukodystrophy showed promising results.
Planning for Gene Therapy Success
With clinical trial successes bringing gene therapy closer to FDA approval and eventual commercialization, it's critical for companies developing gene therapies to understand the marketplace and plan accordingly.
RxC International has put together a white paper containing important information on the current state of gene therapies, companies driving the market forward, and what to consider when beginning the process of commercialization.
Gene Therapy Articles and Other Resources
- Gene Therapies: Pathways for Commercial Success: Commercial success for a gene therapy requires as much consideration as regulatory approval. In this article, RxC International provides key insights into the gene therapy market in conversation with ICER’s white paper for the commercial entrance of gene therapies.
GENE THERAPY: Understanding the Science, Assessing the Evidence, and Paying for Value: The Institute for Clinical and Economic Review (ICER) convened a policy summit in late 2016 to evaluate potential value and challenges of gene therapy treatments. This is a report of their findings and suggestions.